Enliven Therapeutics Q1 net loss narrows as R&D spending reduces

Enliven Therapeutics

07/05/2026 22:12

Overview

US biopharma firm's Q1 net loss narrowed year-over-year as R&D expenses declined

Operating expenses for Q1 decreased compared to the prior year

Company ended Q1 with $452 mln in cash, expected to fund operations into H1 2029

Outlook

Enliven expects to present additional Phase 1 data for ELVN-001 mid-2026

Company plans to initiate Phase 3 ENABLE-2 trial of ELVN-001 in H2 2026

Enliven projects cash runway into the first half of 2029

Result Drivers

LOWER R&D EXPENSES - Co attributed reduced net loss to lower research and development spending in Q1

CLINICAL TRIAL PROGRESS - Enrollment continued in the 80 mg once daily expansion cohort of the Phase 1b trial evaluating ELVN-001 in patients with previously treated CML

Company press release: ID:nPn2q1xj4a

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$23.62 mln
Q1 Basic EPS
-$0.38
Q1 Income From Operations
-$27.82 mln
Q1 Operating Expenses
$27.82 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Enliven Therapeutics Inc is $52.00, about 26.2% above its May 6 closing price of $41.20

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)